January 1, 2013

BLB&G holds Big Pharma accountable with combined $688 million recovery in coordinated securities class actions against Merck & Schering-Plough – among the largest recoveries ever in a case where there was no financial restatement.  On the eve of trial, the second-largest securities class action settlement ever in the Third Circuit brings an end to nearly five years of litigation for investors who suffered losses when negative results of a clinical study for the drug Vytorin became public.